United Therapeutics (NASDAQ:UTHR) Shares Climb 7% – What’s Next?

United Therapeutics Corporation (NASDAQ:UTHR) shares rose 7% during mid-day trading on Wednesday. The stock traded as high as $516.75 and last traded at $515.2770. Approximately 232,095 shares traded hands during trading, a decline of 55% from the average daily volume of 514,759 shares. The stock had previously closed at $481.47.

Key United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: A federal court in Delaware ruled that Liquidia’s Yutrepia infringes two United Therapeutics patents covering inhaled treprostinil for pulmonary hypertension associated with interstitial lung disease (PH-ILD). The court also rejected Liquidia’s arguments that the patents were invalid. United Therapeutics patent litigation announcement
• Positive Sentiment: The decision could limit Yutrepia’s use in the PH-ILD market and potentially support United Therapeutics’ request for FDA action restricting or withdrawing that indication until compliant labeling is approved. Investors view the ruling as improving the durability of Tyvaso-related revenue and cash flow. UTHR prevails in Yutrepia patent dispute
• Positive Sentiment: Some Wall Street commentary turned more bullish following the court victory. The stock also remains supported by strong profitability and prior shareholder returns, including an accelerated share repurchase tied to the company’s $2 billion authorization. United Therapeutics analyst outlook
• Neutral Sentiment: The commercial benefit is not yet guaranteed. Liquidia could pursue further legal action or appeals, while regulatory steps involving Yutrepia may take time.
• Negative Sentiment: Company insiders reported multiple sales. CEO Martine Rothblatt sold 9,500 shares in two transactions, while EVP Paul Mahon sold 8,300 shares for approximately $4.7 million, reducing his position by 15.5%. These sales may reflect scheduled transactions, but the absence of reported insider purchases is a modest sentiment concern. United Therapeutics insider sales

Analysts Set New Price Targets

Several equities research analysts recently weighed in on UTHR shares. The Goldman Sachs Group started coverage on shares of United Therapeutics in a research report on Thursday, September 24th. They issued a “sell” rating and a $321.00 price target on the stock. Bank of America lowered their price objective on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. JPMorgan Chase & Co. boosted their target price on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a report on Thursday, July 23rd. Cantor Fitzgerald restated an “overweight” rating on shares of United Therapeutics in a research report on Thursday. Finally, Royal Bank Of Canada decreased their target price on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. Eleven research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $621.00.

United Therapeutics Stock Performance

The company has a fifty day moving average of $510.03 and a two-hundred day moving average of $539.64. The company has a market cap of $24.51 billion, a PE ratio of 20.44, a price-to-earnings-growth ratio of 2.72 and a beta of 0.49.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping the consensus estimate of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The company had revenue of $783.30 million during the quarter, compared to analyst estimates of $804.65 million. During the same period in the previous year, the firm earned $6.41 earnings per share. United Therapeutics’s quarterly revenue was down 1.9% compared to the same quarter last year. On average, equities analysts forecast that United Therapeutics Corporation will post 26.21 EPS for the current year.

Insider Activity at United Therapeutics

In related news, CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction dated Wednesday, July 8th. The shares were sold at an average price of $553.17, for a total value of $5,255,115.00. Following the sale, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at $22,410,576.21. This represents a 19.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last three months, insiders have sold 365,053 shares of company stock worth $187,906,533. 8.60% of the stock is currently owned by insiders.

Institutional Investors Weigh In On United Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Toth Financial Advisory Corp grew its position in United Therapeutics by 2,400.0% in the 2nd quarter. Toth Financial Advisory Corp now owns 50 shares of the biotechnology company’s stock valued at $27,000 after acquiring an additional 48 shares during the last quarter. Fiduciary Financial Advisors bought a new stake in shares of United Therapeutics during the second quarter worth $30,000. Caitlin John LLC bought a new stake in shares of United Therapeutics during the second quarter worth $37,000. International Assets Investment Management LLC boosted its stake in shares of United Therapeutics by 426.7% during the first quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 64 shares during the period. Finally, Keating Financial Advisory Services Inc. purchased a new stake in shares of United Therapeutics during the second quarter valued at $81,000. 94.08% of the stock is owned by institutional investors.

About United Therapeutics

United Therapeutics Corporation is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH) and other serious cardiopulmonary conditions. The company’s products include Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable form of treprostinil; Orenitram, an oral treprostinil product; and Adcirca, a tadalafil-based PAH treatment.

United Therapeutics markets its therapies primarily in the United States and internationally through commercial and regulatory activities in additional markets.